DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Market Report for Orthopedic Cell Therapy 2017 - MedCore" report to their offering.
There has been much greater interest in bone marrow concentration for use in spinal fusions compared to platelet-rich plasma. The platelet-rich plasma market, on the other hand, is expanding into soft tissue indications. While bone graft substitutes can be soaked in PRP or bone marrow concentrate as an application, the most rapidly growing application, especially for platelet-rich plasma, is for injectables. Such products are directly injected into the site, for example, in a ligament repair or wound operation.
Competition over price is the reason the market values for these segments are not growing as quickly as might be expected. Arthrex significantly brought down the ASP for the market when they introduced their ACP® platelet concentration system, but prices have now largely stabilized in the PRP segment. Test-tube-based products allow for concentration of smaller volumes; these systems reduce ASP further as customers can shift away from higher ASP disposable bucket products.
Key Topics Covered:
1. Research Methodology
2. Disease Overview
2.1 Basic Anatomy
2.2 Disease Pathology And Disorders
2.3 Patient Demographics
3. Product Assessment
3.1 Product Portfolios
3.2 Regulatory Issues And Recalls
3.3 Clinical Trials
4. Orthopedic Cell Therapy Market
4.1 Introduction
4.2 Market Overview
4.3 Market Analysis And Forecast
4.4 Drivers And Limiters
4.5 Competitive Market Share Analysis
Companies Mentioned
- Medtronic
- Genzyme
- DePuy Synthes
- Anika Therapeutics
- Ferring Pharmaceuticals
- Stryker
- NuVasive
- Bioventus
- Zimmer Biomet
- Integra LifeSciences
- RTI Surg
For more information about this report visit http://www.researchandmarkets.com/research/796hhz/us_market_report.
